Skip to content
Peptide research

Thymagen

Also known as Thymogen · EW Dipeptide
Category
Bioregulators
Administration routes
InjectableNasal
Regulatory status
Not FDA-approved

What it is

A dipeptide (Glu-Trp) marketed for immune restoration and healthy aging by acting on T lymphocytes and thymic tissue. Immune-restoration evidence remains limited. Anti-aging is supported by animal work, while Western IM862 oncology trials provide human safety and efficacy data but did not establish cancer benefit. Those trials do not establish safety for healthy-aging use. Effects on tumor biology and hormone pathways remain theoretical concerns. It is not an approved drug in the US, and products sold online are unregulated.

Read Full record

Studied uses & evidence

Studied uses(8)

  • Immune system restoration and T-cell activation

    Medium

    Multiple human studies, including one placebo-controlled trial, show T-cell restoration across conditions.

  • Anti-aging and lifespan extension

    Low

    Single rat study showed longer maximum lifespan, not yet tested in humans.

  • Anti-tumor activity and reduced spontaneous carcinogenesis

    Low

    Reduced tumor incidence in rats, but the same dipeptide failed in several human cancer trials.

Evidence limits

Evidence Level
Mostly Preclinical

Thymagen's clinical evidence is limited and comes almost entirely from Russian clinical studies published in Russian-language journals between 1990-2015. A clinical study in type 1 diabetes patients showed a 94.4% clinical response rate for immunocorrection. Additional clinical experience includes treatment of candidiasis, inflammatory gynecological diseases, and viral infections. In Russia, Thymogen has been used clinically since 1990 as a registered pharmaceutical. None of these studies have been replicated in large, randomized, double-blind Western clinical trials, and the evidence has not been independently validated outside of the Russian research ecosystem. Human evidence also includes a 202-patient Western placebo-controlled phase III trial of IM862/oglufanide that found no superiority in AIDS-related Kaposi sarcoma and possible earlier progression; the Russian surgical trial addresses a different indication. The cited longevity study was in rats; reproducibility and human benefit are not established.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    Not recommended for children outside the indications on the Russian label; not approved in the US.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Limited Western clinical safety data

    High
  • Potential immune over-activation

    Theoretical
  • Endocrine interactions

    Theoretical
  • Research-grade product quality concerns (US market)

    High
  • Unknown long-term effects of chronic use

    Moderate
  • Potential effects on tumor biology

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.